Clinical Trial: DARK STUDY "DysbetalipoproteinemiA and atheRoma Risk"

Study Status: Terminated
Recruit Status: Unknown status
Study Type: Observational

Official Title: Dysbetalipoproteinemia and Atheroma Risk : Assessment of Cardiovascular Risk in Dysbetalipoproteinemic Patients

Brief Summary:

Dysbetalipoproteinemia (type III, Fredrickson's classification) is a rare metabolic disorder. It results from a defect in the clearance of VLDL and chylomicron remnants due to homozygous APOE2 variants or heterozygous APOE mutations, and there is an elevated plasma cholesterol and triglycerides.

As a consequence of the derangements in lipoprotein metabolism, dysbetalipoproteinemia predispose to the premature development of atherosclerosis.

However among this population there is heterogeneity in development of cardiovascular complications and the determinants remain unclear actually.

The aim of the investigators study is to evaluate the intensity of clinical atherosclerosis, and identify its determinants.


Detailed Summary:
Sponsor: Hospices Civils de Lyon

Current Primary Outcome: Computed tomographic measurements for coronary-artery calcium [ Time Frame: Day one : the coronary calcium score is assessed on the date of measurement ]

Comparison with eventual previous examinations.


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Measurement of carotid intima-media by ultrasonography [ Time Frame: Day one : on the date of measurement ]
    Comparison with eventual previous examinations.
  • Measurement of ankle brachial index [ Time Frame: Day one : on the date of measurement ]
    Comparison with eventual previous examinations


Original Secondary Outcome: Same as current

Information By: Hospices Civils de Lyon

Dates:
Date Received: January 2, 2013
Date Started: January 2013
Date Completion: June 2013
Last Updated: January 25, 2013
Last Verified: January 2013